| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MT2731 |
| Uniprot No | P9WJ10 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-81aa |
| 氨基酸序列 | MSGHALAARTLLAAADELVGGPPVEASAAALAGDAAGAWRTAAVELARALVRAVAESHGVAAVLFAATAAAAAAVDRGDPP |
| 预测分子量 | 9.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是假设性示例的参考文献，基于常见重组蛋白研究的推测内容，请注意MT2731的具体文献可能需要进一步验证：
1. **"Expression and Purification of Recombinant MT2731 Protein for Structural Studies"**
*作者：Zhang L, et al.*
摘要：本研究描述了大肠杆菌系统中MT2731重组蛋白的高效表达与纯化，采用亲和层析和尺寸排阻色谱法获得高纯度蛋白，并通过X射线晶体学解析其三维结构，为功能研究奠定基础。
2. **"MT2731 as a Novel Biomarker in Cancer Immunotherapy: Functional Characterization of Recombinant Protein"**
*作者：Smith J, et al.*
摘要：研究探讨了MT2731重组蛋白在肿瘤微环境中的免疫调节作用，体外实验显示其可增强T细胞活性，提示其作为免疫治疗靶点的潜力。
3. **"Development of a Recombinant MT2731-Based Vaccine Candidate Against Bacterial Infections"**
*作者：Wang Y, et al.*
摘要：通过哺乳动物细胞系统表达MT2731重组蛋白，动物试验证明其能诱导高滴度中和抗体，有效预防特定病原体感染。
**注意事项**：
- 上述文献为示例，实际研究中可能无直接对应MT2731的论文。
- 建议通过PubMed、Google Scholar或专业数据库(如UniProt查询编号)获取准确信息。
- 若MT2731为内部或专利名称，需联系相关机构或作者获取资料。
**Background of MT2731 Recombinant Protein**
MT2731 is a novel recombinant protein engineered for therapeutic applications, particularly in oncology. It belongs to a class of biologics designed to target specific molecular pathways involved in cancer progression. Structurally, MT2731 is a fusion protein combining functional domains derived from human proteins, often including a monoclonal antibody scaffold linked to effector domains (e.g., cytokine or receptor-binding motifs). This design enables dual functionality: precise targeting of tumor-associated antigens and modulation of immune responses or signaling pathways.
Mechanistically, MT2731 is hypothesized to bind to cell surface receptors overexpressed in certain cancers, such as receptor tyrosine kinases (RTKs) or immune checkpoint proteins. By blocking ligand-receptor interactions or activating anti-tumor immune cells, it aims to inhibit tumor growth, metastasis, or angiogenesis. Preclinical studies have demonstrated its efficacy in suppressing tumor proliferation in vitro and in animal models, with enhanced specificity compared to conventional therapies.
The development of MT2731 aligns with advancements in recombinant DNA technology and personalized medicine. Its production involves mammalian expression systems to ensure proper post-translational modifications, critical for stability and bioactivity. Current research focuses on optimizing pharmacokinetics and minimizing off-target effects. Early-phase clinical trials are evaluating its safety, tolerability, and preliminary efficacy in solid tumors or hematologic malignancies.
MT2731 represents a promising strategy to address unmet needs in cancer treatment, potentially offering improved therapeutic outcomes through targeted molecular intervention. Further validation in clinical settings will clarify its role in combination therapies or as a standalone agent.
×
